Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 6/20 | 1.00 |
| ▸ | FLT3 | P36888 | 4/20 | 1.00 |
| ▸ | RET | P07949 | 2/20 | 1.00 |
| ▸ | FRK | P42685 | 2/20 | 1.00 |
| ▸ | MAPK9 | P45984 | 2/20 | 1.00 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 1.00 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 1.00 |
| ▸ | BCR | P11274 | 1/20 | 1.00 |
| ▸ | PRKCD | Q05655 | 1/20 | 1.00 |
| ▸ | DDR1 | Q08345 | 1/20 | 1.00 |
| ▸ | TNK1 | Q13470 | 1/20 | 1.00 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 1.00 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 1.00 |
| ▸ | DDR2 | Q16832 | 1/20 | 1.00 |
| ▸ | RPS6KA6 | Q9UK32 | 1/20 | 1.00 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 10/20 | 0.42 |
| ▸ | FGFR3 | P22607 | 5/20 | 0.42 |
| ▸ | BRAF | P15056 | 2/20 | 0.42 |
| ▸ | FLT1 | P17948 | 6/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL275751 | 1.00 | FGFR1 (1.00) | FGFR1FLT3RETFRKMAPK9 | |
| SCHEMBL275381 | 0.97 | FGFR1 (0.95) | FGFR1FLT3RETFRKMAPK9 | |
| SCHEMBL275059 | 0.95 | FGFR1 (0.90) | FGFR1FLT3RETFRKMAPK9 | |
| SCHEMBL277380 | 0.94 | FGFR1 (0.89) | FGFR1FLT3RETFRKMAPK9 | |
| SCHEMBL275980 | 0.93 | FLT3 (0.88) | FGFR1FLT3RETFRKMAPK9 | |
| SCHEMBL277356 | 0.93 | FGFR1 (0.86) | FGFR1FLT3RETFRKMAPK9 | |
| SCHEMBL277233 | 0.92 | FLT3 (0.85) | FGFR1FLT3RETFRKMAPK9 | |
| SCHEMBL276046 | 0.92 | FGFR1 (0.85) | FGFR1FLT3RETFRKMAPK9 | |
| SCHEMBL275816 | 0.92 | FLT3 (0.84) | FGFR1FLT3RETFRKMAPK9 | |
| SCHEMBL275119 | 0.92 | FGFR1 (0.84) | FGFR1FLT3RETFRKMAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025216949-A1 | METHODS FOR TREATING A TUMOR WITH ANTI-CDH6 ANTIBODY DRUG CONJUGATES | ONCUSP THERAPEUTICS, INC. (US) | 2025-10-16 | — | — | WO | claimed |
| US-12357632-B2 | Methods of treating cholangiocarcinoma | QED THERAPEUTICS, INC. (US) | 2025-07-15 | — | — | US | claimed |
| CN-119868564-A | Combined medicine for preventing and/or treating obesity | 海创药业股份有限公司 | 2025-04-25 | — | — | CN | claimed |
| US-12274699-B2 | Methods of treating cholangiocarcinoma | FOUNDATION MEDICINE, INC. (US) | 2025-04-15 | — | — | US | claimed |
| WO-2024093681-A1 | USE OF INFIGRATINIB IN TREATING GASTRIC CANCER AND ADENOCARCINOMA | QED医药股份有限公司 | 2024-05-10 | — | — | WO | claimed |
| US-20230372338-A1 | METHODS OF TREATING CHOLANGIOCARCINOMA | FOUNDATION MEDICINE, INC. (US) | 2023-11-23 | — | — | US | claimed |
| US-11771698-B2 | Methods of treating cholangiocarcinoma | FOUNDATION MEDICINE, INC. (US) | 2023-10-03 | — | — | US | claimed |
| US-20220233536-A1 | METHODS OF TREATING CHOLANGIOCARCINOMA | QED THERAPEUTICS, INC. | 2022-07-28 | — | — | US | claimed |
| EP-3976042-A2 | METHODS OF TREATING CHOLANGIOCARCINOMA | QED Therapeutics, Inc. (US) | 2022-04-06 | — | — | EP | claimed |
| CN-114144180-A | Method for treating bile duct cancer | QED医药股份有限公司 | 2022-03-04 | — | — | CN | claimed |
| WO-2020243273-A9 | METHODS OF TREATING CHOLANGIOCARCINOMA | QED THERAPEUTICS, INC. (US) | 2022-02-10 | — | — | WO | claimed |
| US-20260014253-A1 | CHECKPOINT REGULATOR ANTAGONISTS | GENSUN BIOPHARMA INC (US) | 2026-01-15 | — | — | US | disclosed |
| EP-3954436-B1 | METHOD FOR PRODUCING BIOTISSUE-LIKE STRUCTURE | ORIZURU THERAPEUTICS INC (JP) | 2026-01-07 | — | — | EP | disclosed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| US-12454520-B2 | Protein degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2025-10-28 | — | — | US | disclosed |
| WO-2022040246-A1 | IMMUNE MODULATION OF MYELOID DERIVED SUPPRESSIVE CELL FUNCTION FOR CANCER TREATMENT | STIMIT CORPORATION (US) | 2022-02-24 | — | — | WO | disclosed |
| EP-3472130-B1 | ALIPHATIC PROLINAMIDE DERIVATIVES | Orion Ophthalmology LLC (US) | 2022-02-16 | — | — | EP | disclosed |
| EP-3954436-A1 | METHOD FOR PRODUCING BIOTISSUE-LIKE STRUCTURE | Orizuru Therapeutics, Inc. (JP) | 2022-02-16 | — | — | EP | disclosed |
| WO-2020243273-A9 | METHODS OF TREATING CHOLANGIOCARCINOMA | QED THERAPEUTICS, INC. (US) | 2022-02-10 | — | — | WO | disclosed |
| CN-113993528-A | Method for producing living body-like tissue structure | 千纸鹤治疗公司 | 2022-01-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014253-A1 | CHECKPOINT REGULATOR ANTAGONISTS | PDCD1LG2, PDCD1, CD274 | FGFR1 638/4885FLT3 1484/4885RET 129/4885 |
| US-20230372338-A1 | METHODS OF TREATING CHOLANGIOCARCINOMA | HCCS, PNLIP, LIPA | FGFR1 1732/4885FLT3 1366/4885RET 2804/4885 |
| US-12357632-B2 | Methods of treating cholangiocarcinoma | KRAS, SLC10A2, SLC10A1 | FGFR1 18/4885FLT3 19/4885RET 375/4885 |
| US-12454520-B2 | Protein degraders and uses thereof | MDM2, CUL1, PSMG3 | FGFR1 3094/4885FLT3 2211/4885RET 1003/4885 |
| US-12274699-B2 | Methods of treating cholangiocarcinoma | HCCS, PNLIP, LIPA | FGFR1 1732/4885FLT3 1366/4885RET 2804/4885 |
| US-20220233536-A1 | METHODS OF TREATING CHOLANGIOCARCINOMA | KRAS, SLC10A2, SLC10A1 | FGFR1 18/4885FLT3 19/4885RET 375/4885 |
| US-11771698-B2 | Methods of treating cholangiocarcinoma | HCCS, PNLIP, LIPA | FGFR1 1732/4885FLT3 1366/4885RET 2804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.